Tag Archive for: Series B

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment

/in

Financing to advance lead asset RTX001, an engineered, pro-regenerative macrophage therapy with first-in-class potential for end-stage liver disease, into the Phase I/II EMERALD study Proceeds also strengthen manufacturing capabilities and support macrophage therapy pipeline growth in inflammatory and fibrotic indications beyond liver disease Paul Sekhri, seasoned life sciences executive with decades of drug development and […]

Read more

Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine

/in

Financing led by new investor TCGX, alongside Goldman Sachs Alternatives, Avoro Ventures, and venBio Funding will support and accelerate development of next-generation multivalent respiratory virus vaccines using proprietary Molecular Clamp technology Commenced Phase I clinical study of bivalent vaccine targeting both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) London, UK, 23 September 2024: Vicebio […]

Read more

iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials

/in

• Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors • To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers • To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications Geneva, […]

Read more

NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

/in

Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection London, UK, 22 May 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round. The additional investment […]

Read more

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

/in

Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a […]

Read more